New nanoparticles target cells to reduce gut inflammation
Researchers developed a nanoparticle system to target macrophages and reduce symptoms of colitis in mice.
Scientists developed a macrophage-targeted nanoparticle system called T4(365-378)-NPs. This system uses a TIMD4-derived peptide to reduce colitis symptoms in mice.
Macrophages play a role in the development of inflammatory bowel disease (IBD). TIMD4 is a molecule involved in regulating tissue-resident macrophages. In mice with dextran sulfate sodium (DSS)-induced colitis, TIMD4 expression is elevated in colonic tissues.
The TIMD4 protein stabilizes the LKB1-STRAD-MO25 complex through its intracellular domain. This action activates the AMPK pathway and suppresses NF-κB-dependent chemokine production in macrophages. Reducing TIMD4 increases monocyte infiltration into colonic tissues.
The T4(365-378)-NPs reduced P65 phosphorylation and attenuated DSS-induced colitis. Combining these nanoparticles with anti-47 or anti-TNF- antibodies produced greater improvements than monotherapy. These findings support further preclinical evaluation of TIMD4-derived peptide delivery.
Key facts
- T4(365-378)-NPs reduced colitis symptoms and monocyte recruitment in a mouse model.
- TIMD4 deficiency aggravated DSS-induced colitis and increased monocyte infiltration.
- Combining T4(365-378)-NPs with anti-47 or anti-TNF- antibodies improved results in the DSS-induced colitis model.